The 2025 American Medical Association (AMA) House of Delegates (HOD) Annual Meeting, held in Chicago from June 6-11, was a key platform for ASCO's delegation to engage in robust discussions and ...

On July 14, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule (PFS) proposed rule for Calendar Year (CY) 2026, which includes changes related to ...

On June 27, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a new Innovation Center payment and service delivery model aimed at reducing fraud, waste, and abuse in the Medicare ...

America’s Health Insurance Plans (AHIP)—a trade group representing the U.S. health insurance industry—announced a commitment from participating plansto improve prior authorization processes. The ...

Medicare Advantage Audits Are Expanding. What Do Oncology Practices Need to Know? Continuing its efforts to reduce fraud, waste, and abuse in Medicare, the Centers for Medicare & Medicaid Services ...

A REMS letter for health care providershas been released to address the potential risk of severe hypocalcemia in patients with advanced chronic kidney disease following Jubbonti administration. More ...

The Association for Clinical Oncology (ASCO) is urging lawmakers to prioritize federal cancer research in Fiscal Year (FY) 2026 by providing the National Institutes of Health (NIH), National Cancer ...

As AI use has grown, payers are regularly implementing their own algorithms to deny prior authorization requests. Many of these AI algorithms are proprietary, and there is no clear guidance on if or ...

The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

Main Takeaway Perioperative treatment with durvalumab (Imfinzi) and chemotherapy led to longer survival without cancer recurrence, progression or treatment-related complications for patients with ...

Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer ...